These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25600097)

  • 21. Current understanding of resistance to abiraterone  and enzalutamide in advanced prostate cancer.
    Antonarakis ES
    Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691
    [No Abstract]   [Full Text] [Related]  

  • 22. Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations.
    Mukherji D; Youssef B; Dagher C; El-Hajj A; Nasr R; Geara F; Rabah D; Al Dousari S; Said R; Ashou R; Wazzan W; Jabbour M; Farha G; Al Hamdani N; Al Hallaq Y; Ghazal H; Dbouk H; Bachir B; El Khoury C; Sakr G; Hussain HK; Sayyid K; Ibrahim K; Haidar M; Zouain N; Bitar N; Alameh W; Abbas F; Faddoul S; Nemer E; Assaf G; Farhat F; Bulbul M; Temraz S; Shamseddine A; Gillessen S; Omlin A; Khauli R
    World J Urol; 2020 Mar; 38(3):681-693. PubMed ID: 31297628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
    Oh WK; Miao R; Vekeman F; Sung J; Cheng WY; Gauthier-Loiselle M; Dhawan R; Duh MS
    Med Oncol; 2017 Aug; 34(9):160. PubMed ID: 28795333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
    Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
    BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
    Pagliuca M; Buonerba C; Fizazi K; Di Lorenzo G
    Drugs; 2019 Mar; 79(4):381-400. PubMed ID: 30742279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of advanced prostate cancer.
    von Eyben F; Kiljunen T; Kangasmaki A; Kairemo K; von Eyben R; Joensuu T
    Ann Oncol; 2015 Nov; 26(11):2354. PubMed ID: 26216387
    [No Abstract]   [Full Text] [Related]  

  • 27. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
    Schrader AJ; Boegemann M; Ohlmann CH; Schnoeller TJ; Krabbe LM; Hajili T; Jentzmik F; Stoeckle M; Schrader M; Herrmann E; Cronauer MV
    Eur Urol; 2014 Jan; 65(1):30-6. PubMed ID: 23849416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of alternative antiandrogen therapy for Japanese prostate cancer patients in the era of new hormonal therapy.
    Nakata W; Yamamichi G; Tsujimura G; Tsujimoto Y; Nin M; Tsujihata M
    Int J Urol; 2020 Jan; 27(1):87-89. PubMed ID: 31602723
    [No Abstract]   [Full Text] [Related]  

  • 29. Sequencing of agents in castration-resistant prostate cancer.
    Lorente D; Mateo J; Perez-Lopez R; de Bono JS; Attard G
    Lancet Oncol; 2015 Jun; 16(6):e279-92. PubMed ID: 26065613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hormone therapy in prostate cancer; a pharmacotherapeutic challenge].
    Westdorp H; Benoist GE; Schers HJ; van Erp PH; Gerritsen WR; Mulders PF; Kramers C
    Ned Tijdschr Geneeskd; 2015; 159():A9250. PubMed ID: 26246066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Bone and calcium metabolism associated with malignancy. Bone metastasis of prostate cancer:overview of clinical features and treatments.].
    Suzuki K; Miyazawa Y
    Clin Calcium; 2018; 28(11):1441-1449. PubMed ID: 30373999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary management of advanced prostate cancer: an evolving landscape.
    Khanna A; O'Connor LP; Murthy PB; Bryk DJ; Fascelli M; Ericson K; Yerram NK; Haywood SC; Abouassaly R
    Clin Adv Hematol Oncol; 2021 Feb; 19(2):108-118. PubMed ID: 33596192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
    Badrising S; van der Noort V; van Oort IM; van den Berg HP; Los M; Hamberg P; Coenen JL; van den Eertwegh AJ; de Jong IJ; Kerver ED; van Tinteren H; Bergman AM
    Cancer; 2014 Apr; 120(7):968-75. PubMed ID: 24382803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Primary in Metastatic Prostate Cancer: What Is the Standard of Care?
    Joseph N; Anjanappa M; Choudhury A
    Cancer J; 2020; 26(1):83-86. PubMed ID: 31977390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.
    Barqawi YK; Borrego ME; Roberts MH; Abraham I
    J Med Econ; 2019 Nov; 22(11):1202-1209. PubMed ID: 31452414
    [No Abstract]   [Full Text] [Related]  

  • 36. New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
    Wilson L; Tang J; Zhong L; Balani G; Gipson G; Xiang P; Yu D; Srinivas S
    J Oncol Pharm Pract; 2014 Dec; 20(6):417-25. PubMed ID: 24243919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer.
    Markowski MC; Pienta KJ
    Asian J Androl; 2015; 17(6):936-8; discussion 938. PubMed ID: 25865849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer.
    Schmid SC; Geith A; Böker A; Tauber R; Seitz AK; Kuczyk M; von Klot C; Gschwend JE; Merseburger AS; Retz M
    Adv Ther; 2014 Feb; 31(2):234-41. PubMed ID: 24442834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
    Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
    Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
    Cursano MC; Iuliani M; Casadei C; Stellato M; Tonini G; Paganelli G; Santini D; De Giorgi U
    Crit Rev Oncol Hematol; 2020 Feb; 146():102864. PubMed ID: 31986318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.